Literature DB >> 1903413

A novel differentiation antigen on human monocytes that is specifically induced by granulocyte-macrophage colony-stimulating factor or IL-3.

K Maeda1, S Sone, Y Ohmoto, T Ogura.   

Abstract

A mouse mAb (TOMS-1) was generated against human blood monocytes that had been cultured for 4 days in medium with recombinant human granulocyte-macrophage CSF (GM-CSF). TOMS-1 (IgG1) detected a unique cell surface Ag with a molecular mass of about 43 kDa under both reducing and nonreducing conditions. TOMS-1Ag was expressed on monocytes treated with GM-CSF, but not on fresh or untreated monocytes. This Ag was induced dose dependently during culture of monocytes with GM-CSF for more than 24 h, reaching a maximum level in 3 or 4 days. Treatment of monocytes with cycloheximide in the presence of GM-CSF blocked TOMS-1Ag induction completely, indicating that de novo protein synthesis was required for its expression. TOMS-1Ag was also induced by treatment of monocytes with IL-3, but not with other cytokines such as macrophage-CSF, IL-4, and IFN-gamma or stimulators including LPS, desmethyl muramyl dipeptide, and PMA. TOMS-1Ag expression induced by GM-CSF was up-regulated by IL-4, but down-regulated by IFN-gamma. TOMS-1Ag was not induced on lymphocytes, granulocytes, or AM by GM-CSF or appropriate stimuli. TOMS-1Ag was also not expressed on any cell lines of human leukemias or solid tumors examined. Thus, TOMS-1Ag is a monocyte-specific differentiation Ag induced by GM-CSF or IL-3. These results suggest that TOMS-1 should be useful for monitoring the process of monocyte differentiation by GM-CSF or IL-3.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1903413

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  5 in total

1.  Intermediate stages in monocyte-macrophage differentiation modulate phenotype and susceptibility to virus infection.

Authors:  K C McCullough; S Basta; S Knötig; H Gerber; R Schaffner; Y B Kim; A Saalmüller; A Summerfield
Journal:  Immunology       Date:  1999-10       Impact factor: 7.397

2.  Recombinant Granulocyte-Macrophage Colony-Stimulating Factor (rGM-CSF) : A Review of its Pharmacological Properties and Prospective Role in the Management of Myelosuppression.

Authors:  Susan M Grant; Rennie C Heel
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

3.  Immunological circumvention of multiple organ metastases of multidrug resistant human small cell lung cancer cells by mouse-human chimeric anti-ganglioside GM2 antibody KM966.

Authors:  M Hanibuchi; S Yano; Y Nishioka; H Yanagawa; T Miki; S Sone
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

4.  Plasma interleukin-3 and interleukin-4 concentrations in Turkish asthmatic children.

Authors:  N Kutukculer; E Ozdogru; E Demir; R Tanac
Journal:  Arch Dis Child       Date:  1995-10       Impact factor: 3.791

5.  Anti-ganglioside GM2 monoclonal antibody-dependent killing of human lung cancer cells by lymphocytes and monocytes.

Authors:  M Hanibuchi; S Yano; Y Nishioka; H Yanagawa; S Sone
Journal:  Jpn J Cancer Res       Date:  1996-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.